ArticleDigestive diseases and sciences2026
Lactated Ringer's Solution at a Standard Infusion Rate in Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis Prevention: A Retrospective Comparative Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is a common complication, and its prevention remains challenging. Although aggressive infusion of lactated Ringer's solution (hereafter Lactated Ringer's) has shown preventive effects, the efficacy of standard infusion rates remains unclear.
aimTo evaluate whether lactated Ringer's administered at a standard rate reduces the incidence or severity of post-ERCP pancreatitis compared with non-lactated Ringer's solutions.
methodsThis single-center retrospective study compared patients who received non-lactated Ringer's solutions before January 2019 with those who received lactated Ringer's after January 2019, at a standard rate. The outcomes were post-ERCP pancreatitis incidence, severity, C-reactive protein (CRP) level, and systemic inflammatory response syndrome (SIRS).
resultsOf 1194 patients included (median age, 71 years; 60% male), pancreatitis occurred in 5.6% (30/529) of the non-lactated Ringer's group and 5.3% (35/665) of the lactated Ringer's group (P = 0.76). Severe or moderately severe pancreatitis occurred in six patients each in both groups (approximately 1%). Mean CRP level at 24 h was similar between the groups (1.26 vs. 1.44 mg/dL, P = 0.75), and SIRS rates at 24/48 h did not differ significantly (P = 0.61 and 1.00). Multivariate analysis identified pancreatic injection, naïve papilla, and female sex as independent risk factors; fluid type was not associated with outcome (OR 1.09, P = 0.76).
conclusionsLactated Ringer's at a standard infusion rate did not reduce the incidence or severity of post-ERCP pancreatitis compared with a non-lactated Ringer's solution. Further research is required to optimize fluid therapy for preventing this complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.